Answers are grounded in this paper and cite their sources.
Antimicrobial resistance represents one of the most critical global public health challenges. Increasing evidence suggests that rare actinomycetes can harbour novel biosynthetic diversity to produce antimicrobial compounds. This work explores the capabilities for the biosynthesis of antimicrobial natural products of Salinibacterium sp. AL4.1, in contrast with those of Salinibacterium sp. VpJ6, through a comparative metabologenomic approach. Comparative bioactivity tests using both Salinibacterium strains AL4.1 and VpJ6 revealed antimicrobial bioactivity of crude extracts from strain AL4.1 against Staphylococcus aureus . Liquid chromatography coupled with tandem mass spectrometry was performed on the tested samples, allowing for metabolite dereplication as well as identification of bioactivity-associated features. This revealed the presence of potential aromatic polyketides structurally related to known bioactive compounds such as phloretin, for which bacterial production had not been reported to date, as well as other potentially novel alkaloids and peptides. The genomes of both strains were sequenced and mined for their biosynthetic capabilities and further compared to those of other Salinibacterium strains with available genomic data. Phylogenomic studies suggested that both strains AL4.1 and VpJ6 could represent potentially new species. A mainly phylogeny-dependent distribution of biosynthetic gene clusters (BGCs) was observed, emphasizing the presence of a widely distributed type III polyketide synthase BGC, which could be linked to the bioactive compounds. These results suggest that Salinibacterium sp. AL4.1 can produce novel bioactive natural products, and the genus Salinibacterium holds relevant and underexplored biosynthetic potential.
No takes yet. Share an insight, caveat, or question.
Sánchez-Carvajal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: